Philippe Connes

The paper identifies Otenabant, a CB1 antagonist, as a potent and selective PIEZO1 inhibitor through high-throughput screening and validates its effects across multiple assays.

This study shows that long-distance trail running causes inflammation, lipid, and purine oxidation in red blood cells, indicating systemic inflammation and metabolic changes as key factors in RBC damage.

This study uses DPD simulations to analyze how altered RBC properties in Gaucher Disease affect blood viscosity and bone health through three shear rate domains.